Effectiveness of switching between TNF inhibitors in ankylosing spondylitis: data from the NOR-DMARD register.
about
Predictors of Switching Anti-Tumor Necrosis Factor Therapy in Patients with Ankylosing SpondylitisSwitching between TNF inhibitors in psoriatic arthritis: data from the NOR-DMARD study.Ankylosing spondylitis in iran; late diagnosis and its causes.Advances in managing ankylosing spondylitisDoes the reason for discontinuation of a first TNF inhibitor influence the effectiveness of a second TNF inhibitor in axial spondyloarthritis? Results from the Swiss Clinical Quality Management Cohort.Persistence and costs with subcutaneous TNF-alpha inhibitors in immune-mediated rheumatic disease stratified by treatment line.The immunogenicity to the first anti-TNF therapy determines the outcome of switching to a second anti-TNF therapy in spondyloarthritis patients.Efficacy and safety of adalimumab treatment in patients with rheumatoid arthritis, ankylosing spondylitis and psoriatic arthritis.Treatment challenges in axial spondylarthritis and future directions.Adalimumab for the treatment of ankylosing spondylitis and nonradiographic axial spondyloarthritis - a five-year update.Certolizumab pegol in axial spondyloarthritis.Therapeutic options after treatment failure in rheumatoid arthritis or spondyloarthritides.Ustekinumab for the treatment of patients with active ankylosing spondylitis: results of a 28-week, prospective, open-label, proof-of-concept study (TOPAS).Tumor necrosis factor-α (TNFα) inhibitors in the treatment of nonradiographic axial spondyloarthritis: current evidence and place in therapy.An update on the use of tumor necrosis factor alpha inhibitors in the treatment of ankylosing spondylitis.The influence of ERAP1 gene variants on clinical phenotype in ankylosing spondylitis.Primary inefficacy of TNF inhibitors in patients with axial spondyloarthritis: a long-term follow-up of 25 patients.Drug survival of anti-tumour necrosis factor α therapy in spondyloarthropathies: results from the Spanish emAR II Study.Etanercept for patients with psoriasis who did not respond or who lost their response to adalimumab or infliximab.Switching from originator biological agents to biosimilars: what is the evidence and what are the issues?Switching biological disease-modifying antirheumatic drugs in patients with axial spondyloarthritis: results from a systematic literature reviewRecommendations for the management and treatment of ankylosing spondylitis.Clinical response, drug survival and predictors thereof in 432 ankylosing spondylitis patients after switching tumour necrosis factor α inhibitor therapy: results from the Danish nationwide DANBIO registry.Cost-Effectiveness of Golimumab in Ankylosing Spondylitis from the UK Payer Perspective.Treatment patterns of biologics in US patients with ankylosing spondylitis: descriptive analyses from a claims database.Drug survival of tumor necrosis factor α inhibitors in patients with ankylosing spondylitis in Korea.Drug survival and causes of discontinuation of the first anti-TNF in ankylosing spondylitis compared with rheumatoid arthritis: analysis from BIOBADABRASIL.[German Society for Rheumatology S3 guidelines on axial spondyloarthritis including Bechterew's disease and early forms: 8.4 Pharmaceutical therapy, 8.5 Evaluation of therapy success of pharmaceutical measures].Opportunities and challenges for real-world studies on chronic inflammatory joint diseases through data enrichment and collaboration between national registers: the Nordic example.Impact of extra-articular spondyloarthritis manifestations and comorbidities on drug retention of a first TNF-inhibitor in ankylosing spondylitis: a population-based nationwide study
P2860
Q28546596-7E5D0E05-A075-4242-824C-190C40D69588Q30612910-052F7560-748E-40AB-BE6D-891084247B3BQ33640595-F984BCFC-2CE9-40A0-A8F2-2C43B5D544D7Q34201927-FD359E7A-5402-47E0-AAE8-F4406BCC5060Q36715135-F8500A23-B012-44D3-9F19-267BFE93BB65Q37596119-F5CEEB72-EC15-436B-A3AE-DE520E050616Q37690355-5CD6FE96-8A3D-47AA-B9F1-236DAA4E53EFQ37873493-3322CC52-FC1D-4209-9997-390552CE659EQ38124281-F329F45F-0764-4E6F-BA54-0D3149D35044Q38145501-A34D8FA9-0CDF-485B-A21A-A66237451662Q38161555-17020A51-2F92-47FC-9934-CE3F6932892BQ38238931-444B1534-2226-44DF-B8D6-1171B95D122EQ38438153-B1D5AE8A-F76E-43B9-8693-5CBF3DBCE756Q38611064-3796ADE5-3FC9-4528-8CB5-548BA6FA4DE0Q38914839-CF771D9A-FCC9-4FB9-A08A-963F14F5D641Q39838349-2947B4A0-7850-4694-BA5F-DA96AEA9A373Q40386650-B2073D79-C4B0-45A0-AD94-90E2F3D81640Q41231679-775FC58D-984B-4C08-8499-EB618BB2EB15Q41561618-A8115AB7-D262-4810-90FA-E109ECD5FCF0Q42360803-31550E19-B594-49D1-BEFE-7711B35178BEQ42701796-CC231CF8-AFAE-4E2A-8E09-DDB6F1E3D113Q44898441-09E297CC-706E-4731-AC16-E40301BA3008Q45229094-78FE9A47-4D09-44A0-A7D4-B74F73B89AE9Q45893661-40D3671B-BE0D-4CF2-8066-11ABF16288F8Q47705810-D5F3283B-4C1B-4D4B-8077-BF6DCA60669DQ47983950-F8C185A1-6CA8-4863-AFCD-D1CDC1B479C2Q51036235-BF3098B4-0E5A-42EB-8823-23629CAD17D0Q52874129-D2378A26-FFC5-4AEE-B5EF-6F36DEB789EFQ55338290-222AB834-BF20-4D9E-A853-DC08F3CED0B6Q58566050-491B7969-2896-47D9-9E8E-9A62D8E0D2A0
P2860
Effectiveness of switching between TNF inhibitors in ankylosing spondylitis: data from the NOR-DMARD register.
description
2010 nî lūn-bûn
@nan
2010 թուականի Նոյեմբերին հրատարակուած գիտական յօդուած
@hyw
2010 թվականի նոյեմբերին հրատարակված գիտական հոդված
@hy
2010年の論文
@ja
2010年論文
@yue
2010年論文
@zh-hant
2010年論文
@zh-hk
2010年論文
@zh-mo
2010年論文
@zh-tw
2010年论文
@wuu
name
Effectiveness of switching bet ...... a from the NOR-DMARD register.
@ast
Effectiveness of switching bet ...... a from the NOR-DMARD register.
@en
type
label
Effectiveness of switching bet ...... a from the NOR-DMARD register.
@ast
Effectiveness of switching bet ...... a from the NOR-DMARD register.
@en
prefLabel
Effectiveness of switching bet ...... a from the NOR-DMARD register.
@ast
Effectiveness of switching bet ...... a from the NOR-DMARD register.
@en
P2093
P50
P356
P1476
Effectiveness of switching bet ...... a from the NOR-DMARD register.
@en
P2093
C Kaufmann
E Rødevand
K Mikkelsen
W Koldingsnes
P304
P356
10.1136/ARD.2010.131797
P407
P577
2010-11-09T00:00:00Z